{"id":"al8326-high-dose-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce inflammation in conditions driven by excessive immune activation, particularly in respiratory and inflammatory diseases.","oneSentence":"AL8326 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:20:42.593Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory airway disease (Phase 2 development)"}]},"trialDetails":[{"nctId":"NCT05363280","phase":"PHASE2","title":"Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advenchen Pharmaceuticals, LLC.","startDate":"2022-11-01","conditions":"Small Cell Lung Cancer","enrollment":36},{"nctId":"NCT05486598","phase":"PHASE1","title":"A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects","status":"UNKNOWN","sponsor":"Advenchen Laboratories Nanjing Ltd.","startDate":"2022-06-21","conditions":"Diet, High-Fat, Pharmacokinetics","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AL8326 high dose group","genericName":"AL8326 high dose group","companyName":"Advenchen Pharmaceuticals, LLC.","companyId":"advenchen-pharmaceuticals-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AL8326 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Inflammatory airway disease (Phase 2 development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}